PlainRecalls
FDA Drug Moderate Class II Ongoing

Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67

Reported: January 21, 2026 Initiated: January 2, 2026 #D-0290-2026

Product Description

Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67

Reason for Recall

Presence of Particulate Matter.

Details

Recalling Firm
Cipla USA, Inc.
Units Affected
15,221 syringes
Distribution
Nationwide in the USA
Location
Warren, NJ

Frequently Asked Questions

What product was recalled?
Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67. Recalled by Cipla USA, Inc.. Units affected: 15,221 syringes.
Why was this product recalled?
Presence of Particulate Matter.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 21, 2026. Severity: Moderate. Recall number: D-0290-2026.